Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecAiforia TechnologiesBiohitOrionModulight

Latest content

ShowingAll content types

Bioretec: Offering to be completed in April

Research 30.03.2026 klo 10.04 by Antti Siltanen
Bioretec

US market roadmap for medical devices – a European perspective

Analyst Comment 27.03.2026 klo 12.45 by Antti Siltanen
BioretecAiforia TechnologiesNightingale HealthNexstim

Nexstim received new sales clearances in the United States

Analyst Comment 24.03.2026 klo 09.18 by Antti Siltanen
Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

Aiforia secures another CE-IVD mark

Analyst Comment 18.03.2026 klo 08.41 by Antti Siltanen
Aiforia Technologies

Aiforia H2’25: Green shoots on the clinical side

Video 16.03.2026 klo 11.29 by Antti Siltanen, Isa Hudd
Aiforia Technologies

Faron:

Research 12.03.2026 klo 10.27 by Antti Siltanen
Faron Pharmaceuticals

New partnership for Aiforia

Analyst Comment 11.03.2026 klo 08.49 by Antti Siltanen
Aiforia Technologies

Terms of Faron's rights offering have been published

Analyst Comment 11.03.2026 klo 08.33 by Antti Siltanen
Faron Pharmaceuticals

Bioretec is planning rights issue worth 5-15 MEUR

Analyst Comment 11.03.2026 klo 08.45 by Antti Siltanen
Bioretec

Aiforia H2'25: Green shoots on the clinical side

Research 09.03.2026 klo 10.51 by Antti Siltanen
Aiforia Technologies
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.